Michael A. Ihnat

Contact Information:
Michael A. Ihnat



 

Ihnat, Michael A. (HSC)
Associate Professor

Department of:

College Of Pharmacy/Pharmaceutical Sciences -Associate Professor

Center of:

Education:

Dartmouth Medical School, Hanover, NH   Ph.D. (Pharmacology and Toxicology)   1997
The Ohio State University.   B.S. - Pharmacy   1989
The University of Cincinnati   Pre-pharmacy and electrical engineering curriculum   1985

Professional Interest/Expertise/Specializations:
The interest in our laboratory is pre-clinical drug development. We have two major current areas of focus - cancer and inflammatory diseases. We have partnered with medicinal chemists and biomedical researchers to target molecules involved in inflammation, carcinogenesis, metastasis, angiogenesis, and bone formation. Some specific projects ongoing in our laboratory are: 1) With Dr. Aleem Gangjee at Duquesne University to create dual TKI/cytotoxic anticancer molecules to target triple negative and basal-like breast cancer and together with Dr. Rheal Towner at the Oklahoma Medical Research Foundation to treat aggressive glioma multforme. 2) With Drs. Pui-Kai Li and Chenglong Li at The Ohio State University, Dr. Thomas Sferra in the Department of Pediatrics and Dr. Randle Galucci in the Department of Pharmaceutical Sciences to create novel molecules targeting the IL-6 signaling pathway at both the level of its receptor and at downstream signaling points (STAT3) for the treatment of inflammation bowel disease, colon carcinogenesis, cancer therapy, wound healing and refractory dermatitis. 3) With Dr. Robert Hurst in the Department of Urology to dicover molecules capable of trageting suppressed cancer cells before they reactivate. 4) With Dr. Sukyung Woo in the Department of Pharmaceutical Sciences to determine whether the above molecules have synergistic anticancer effects when added together with conventional agents. 5) With Dr. Tarisai Dandajena in the Department of Cell Biology/Colleges of Dentistry at the OUHSC to find molecules capable of speeding up tooth movement via increased antiogenesis and osteoclastogenesis.

Websites:

Dr. Ihnat website profile

Research Projects:

Single agents with designed combination chemotherapy potential (NIH/NCI)
Cooperativity between ETS factor ETV1 and JMJD2 histone demethylases in prostate cancer (OU Cancer)
Development of a novel agent, DT-320, for the treatment of aggressive breast cancer. (OCAST-OARS)
Phase II SBIR grant: Drugs targeting dormant tumors as anti-metastatic agents (NIH/NCI)
The role of IL-6 receptor in irritant dermatitis (SDC/NIOSH)

Selected Publications:

Pro-growth Role of the JMJD2C Histone Demethylase in HCT-116 Colon Cancer Cells and Identification of Curcuminoids as JMJD2 Inhibitors.
2015    Kim T-D, Fuchs JR, Schwartz E, Abdelhamid D, Etter J, Berry WL, Li C, Ihnat MA, Li PK, Janknect R.
Am J Translational Res
The Design and Discovery of WAter Soluble 4-substituted-2,6-dimethylfuro{2,3-d}pyrimidines as Multitargeted REceptor Tyrosine Kinase Inhibitors and Microtubule Targeting Antitumor Agents
2015    Zhang X, Raghavan S, Ihnat M, Thorpe JE, Disch BC, Bastian A, et al.
Bioorganic Med Chem
Evaluation of 99mTc-probestin for imaging APN expressing tumors by SPECT
2013    Pathuri G, Hedrick AF, Awasthi V, Ihnat MA, Gali H
Bioorg. Med. Chem. Lett.
Synthesis and Biological Activity of 5-chloroN4-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as Vascular Endothelial Growth Factor
2013    Ganjee A, Zaware N, Raghavan S, Dish BC, Thorpe JE, Bastian A, Ihnat MA.
Bioorganic Med Chem
IL-6 deficiency Exacerbates Inflammation in a Mouse Model of Irritant Dermatitis
2012    Lee EG, Mickle-Kawar BM, Ihnat MI, Gallucci RM
J. Immunotox
Synthesis and Biodistribution Studies of Technetium-99m-labeled Aminopeptidase N Inhibitor Conjugates
2012    Pathuri G, Hedrick AF, Disch BC, Ihnat MA, Awasthi V, Gali H.
Bioorganic & Medicinal Chemistry Letters
Synthesis and Evaluation of Novel Tc-99m Labeled Probestin Conjugates for Imaging APN/CD13 Expression in vivo.
2012    Ihnat MA, Awasthi V, Gali H.
Bioconjugate Chem
Enhanced angiogenesis of modified porcine small intestinal submucosa with hyaluronic acid-poly(lactide-co-glycolide) nanoparticles: From fabrication to preclinical validation.
   Mondalek FG, Ashley RA, Roth CC, Kibar Y, Shakir N, Ihnat MA, Fung KM, Grady BP, Kropp BP, Lin HK.
J Biomed Mater Res A 2010; 94(3): 712-719
Curcumin and turmeric attenuate arsenic-induced angiogenesis in ovo.
   Pantazis P, Varman A, Simpson-Durand C, Thorpe J, Ramalingam S, Subramaniam D, Houchen C, Ihnat M, Anant S, Ramanujam RP.
Altern Ther Health Med 2010; 16: 12-14
Docosahexaenoic acid inhibits superoxide dismutase I gene transcription in human cancer cells: The involvement of PPAR(alpha) and HIF-2(alpha) signaling.
   Tulier ER, Beavers CT, Lou JR, Benbrook DM, Ihnat MA, Ding WQ.
Mol Pharmacol 2009; 76(3): 588-595
Docosahexaenoic acid inhibits superoxide dismutase I gene transcription in human cancer cells: The involvement of PPAR(alpha) and HIF-2(alpha) signaling.
   Tulier ER, Beavers CT, Lou JR, Benbrook DM, Ihnat MA, Ding WQ.
Mol Pharmacol 2009; 76(3): 588-595.
Design, synthesis and x-ray cyrstal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors.
   Gangjee A, Li W, Lin L, Zeng Y, Ihnat M, Warnke LA, Green DW, Cody V, Pace J, Queener SF
Bioorg Med Chem 2009; 17: 7324-7336.
Long-term glycemic control influences the long-lasting effect of hyperglycemia on endothelial function in type I diabetes.
   Ceriello A, Esposito K, Ihnat M, Thorpe J, Guigliano D.
J Clin Endocrinol Metab 2009; 94(8): 2751-2756
Simultaneous control of hyperglycemia and oxidative stress normalizes enhanced thrombin generation in type 1 diabetes.
   Ceriello A, Esposito K, Ihnat M, Zhang J, Giugliano D.
J Thromb Haemost 2009; 7(7): 1228-1230.
Clinical review 2: The "metabolic memoriy" is more than just a tight glucose control necessary to prevent diabetic complications?
   Ceriello A, Ihnat MA, Thorpe JE.
J Clin Endocrinol Metab 2009; 94(2): 410-415.
Chronic exposure to arsenic in the drinking water alters the expression of immune response genes in mouse lung.
   Kozul CD, Hampton TH, Davey JC, Gosse JA, Nomikos AP, Thorpe JE, Eisenhauer PI, Weiss DJ, Ihnat MA, Hamilton JW.
Environ Health Perspect 2009; 7(7): 1108-1115
The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines.
   Gangjee A, Namjoshi OA, Ihnat MA, Buchanan A.
Bioorg Med Chem Lett 2010; 20(10): 3177-3181
Novel STQAT3 phyosphorlyation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells.
   Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, Pandit B, Ihnat MA, Shenoy SS, et al.
Cancer Res 2010; 70: 2445-2454
Single agents with designed combination chemotherapy potential: Synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.
   Gangjee A, Zaware N, Raghaven S, Ihnat M, Shenoy S, Kisliuk RL.
J Med Chem 2010; 53: 1563-1578
Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrol[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and anti-angiogenic and antitumor agents.
   Gangjee A, Kurup S, Ihnat MA, Thorpe JE, Shenoy SS.
Bioorg Med Chem; 18(10): 3575-2587
Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.
   Gangjee A, Zhao Y, Raghaven S, Ihnat MA, Disch BC.
Bioorg Med Chem; 18(14): 5261-5273
Effect of acute hyperglycaemia, long-term glycaemic control and insulin on endothelial dysfunction and inflammation in Type 1 diabetic patients with different characteristics.
   Ceriello A, Esposito K, Ihnat M, Thorpe j, Giugliano D.
Diabet Med; 27: 911-917
Reply to Kilpatrick et al.
   Ceriello A, Ihnat M
Diabet Med 2010; 27: 968
http://onlinelibrary.wiley.com/doi/10.1111/j.1464-5491.2010.02931.x/abstract
Glycaemic variability: A new therapeutic challenge in diabetes and the critical care setting.
   Ceriello A, Ihnat MA.
Diabet Med; 27: 862-867